1-12 of 12
Michael Hudecek, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ATRA Augments BCMA Expression on Myeloma Cells and Enhances Recognition By BCMA-CAR T-Cells

Estefania Garcia-Guerrero, PhD, Luis Gerardo Rodríguez-Lobato, Sophia Danhof, MD, Belén Sierro-Martínez, Ralph Goetz, Markus Sauer, Jose A. Perez-Simon, MD PhD, Hermann Einsele, MD, Michael Hudecek, MD, Sabrina Prommersbe
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-142572
Published: 2020
Journal Articles

RAC1 Inhibitor EHT1864 and Venetoclax Overcome Midostaurin Resistance in Acute Myeloid Leukemia

Andoni Garitano-Trojaola, PhD, Ana Sancho, Ralph Goetz, Susanne Walz, Hardikkumar Jetani, Eva Teufel, Nadine Rodhes, Matteo DaVia, MD, Larissa Haertle, PhD, Silvia Nerreter, Cornelia Vogt, MSc, Johannes Duell, MD, Raoul Tibes, MD PhD, Sabrina Kraus, Andreas Rosenwald, MD, Leo Rasche, MD, Michael Hudecek, MD, Markus Sauer, Hermann Einsele, MD, Jürgen Groll, Martin Kortüm, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1277.
https://doi.org/10.1182/blood-2019-129762
Published: 2019
Journal Articles

FLT3 Inhibitor Treatment Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CAR-T Cells

Hardikkumar Jetani, Irene García-Cadenas, Thomas Nerreter, Ralph Goetz, Jorge Sierra, MD, Halvard Bonig, MD, Markus Sauer, Hermann Einsele, MD, Michael Hudecek, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 903.
https://doi.org/10.1182/blood-2018-99-118171
Published: 2018
Journal Articles

Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Matteo Giovanni Carrabba, MD, Monica Casucci, PhD, Michael Hudecek, MD, Concetta Quintarelli, PhD, Javier Briones, MD, Roman Hajek, MD PhD, Jorge Sierra, MD, Franco Locatelli, Hermann Einsele, MD PhD, Claudio Bordignon, MD, Fabio Ciceri, MD, Catia Traversari, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5790.
https://doi.org/10.1182/blood-2018-99-117974
Published: 2018
Journal Articles

A Novel Pharmacologic 'Remote Control' to Steer CAR-T Cell Function In Vivo

Katrin Mestermann, Julian Rydzek, Frenz Silke, Thomas Nerreter, Mades Andreas, Hermann Einsele, MD, Michael Hudecek, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2055.
https://doi.org/10.1182/blood-2018-99-118626
Published: 2018
Journal Articles

Panobinostat Induces Upregulation of CD38 and Augments the Anti-Myeloma Efficacy of Daratumumab in Pre-Clinical Models

Estefania Garcia-Guerrero, Tea Gogishvili, PhD, Sophia Danhof, MD, Martin Schreder, MD, Celine Pallaud, PhD, Thomas Lehmann, PhD, Hermann Einsele, MD, Michael Hudecek, MD
Journal: Blood
Blood (2016) 128 (22): 4481.
https://doi.org/10.1182/blood.V128.22.4481.4481
Published: 2016
Journal Articles

CAR-Engineered T Cells Specific for the Elotuzumab Target SLAMF7 Eliminate Primary Myeloma Cells and Confer Selective Fratricide of SLAMF7+ Normal Lymphocyte Subsets

Sophia Danhof, MD, Tea Gogishvili, PhD, Silvia Koch, Martin Schreder, MD, Stefan Knop, Hermann Einsele, Michael Hudecek, MD
Journal: Blood
Blood (2015) 126 (23): 115.
https://doi.org/10.1182/blood.V126.23.115.115
Published: 2015
Journal Articles

Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition

Cameron J Turtle, MBBS, PhD, Daniel Sommermeyer, PhD, Carolina Berger, MD, Michael Hudecek, MD, David M Shank, Natalia N Steevens, BS, Tanya M Budiarto, BSc, Mandana Karimi, MS, Colette N Chaney, RN, Anna Marie DeVito, RN, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R Riddell, MD, David G Maloney, MDPhD
Journal: Blood
Blood (2014) 124 (21): 384.
https://doi.org/10.1182/blood.V124.21.384.384
Published: 2014
Journal Articles

Selecting T-Cell Subsets for Adoptive T-Cell Therapy to Optimize Potency and Persistence

Stanley Riddell, MD, Cameron Turtle, Michael Hudecek, MD, Daniel Sommermeyer, Ph.D, Michael C. Jensen, MD
Journal: Blood
Blood (2013) 122 (21): SCI-39.
https://doi.org/10.1182/blood.V122.21.SCI-39.SCI-39
Published: 2013
Journal Articles

The Non-Signaling Extracellular Spacer Domain of CD19-Specific Chimeric Antigen Receptors Is Decisive for in Vivo Anti-Tumor Activity

Michael Hudecek, MD, Anne Silva, MD, Paula L. Kosasih, BSc, Yvonne Y. Chen, PhD, Cameron J. Turtle, MBBS, PhD, Michael C. Jensen, MD, Stanley R. Riddell, MD
Journal: Blood
Blood (2012) 120 (21): 951.
https://doi.org/10.1182/blood.V120.21.951.951
Published: 2012
Journal Articles

Naïve CD4+ T Cells Modified to Express a ROR1-Specific CAR Mediate Anti-Tumor Activity and Provide Superior Help to CD8+ ROR1-CAR T Cells

Michael Hudecek, MD, Maria-Teresa Lupo-Stanghellini, MD, Paula Kosasih, BSc, Jeannette Bet, MSc, Paulina Paszkiewicz, MSc, David G. Maloney, MD, PhD, Michael C. Jensen, MD, Christoph Rader, Ph.D., Stanley R. Riddell, MD
Journal: Blood
Blood (2011) 118 (21): 643.
https://doi.org/10.1182/blood.V118.21.643.643
Published: 2011
Journal Articles

CD8 + T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor Specifically Recognize ROR1 Positive B Cell Tumors.

Michael Hudecek, MD, Thomas M Schmitt, PhD, Sivasubramanian Baskar, PhD, Wen-Chung Chang, David G Maloney, MD, PhD, Michael C Jensen, M.D., Christoph M. Rader, Ph.D., Stanley Riddell, MD
Journal: Blood
Blood (2009) 114 (22): 930.
https://doi.org/10.1182/blood.V114.22.930.930
Published: 2009